Faes Farma SA

Research Faes Farma SA (FAE) on Bullrun: market cap EUR 1.48B, P/E 17.6, dividend yield 2.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 1.48B; P/E is 17.6; dividend yield is 2.7%.

Peer valuation comparison

Latest P/E is 17.61x versus a Healthcare sector median of 24.61x (28.4% below).

Latest dividend yield is 2.67% versus a Healthcare sector median of 1.84% (45.1% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 626.99MEUR 79.63MEUR 62.39M63.8%0.25EUR 117.31MEUR 433.29MEUR 745.59M
FY2024EUR 510.04MEUR 111.36MEUR 81.65M65.9%0.36EUR 64.22MEUR 26.29MEUR 726.62M
FY2023EUR 473.09MEUR 91.90MEUR 5.21M66.0%0.3EUR 34.65MEUR 28.51MEUR 663.41M
FY2022EUR 461.72MEUR 89.50MEUR 31.83M64.8%0.29EUR 66.41MEUR 37.04MEUR 602.40M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-09-28EUR 1.48B17.62.7%0.13

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.13 EUR, yield 2.7%.

YearDividends/share
FY20250.18 EUR
FY20240.16 EUR
FY20230.04 EUR
FY20220.03 EUR

About Faes Farma SA

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Faes Farma SA's market cap?

Faes Farma SA's market capitalization is EUR 1.48B.

What is Faes Farma SA's P/E ratio?

Faes Farma SA's price-to-earnings (P/E) ratio is 17.6.

Does Faes Farma SA pay a dividend?

Faes Farma SA has a dividend yield of 2.7%.

What does Faes Farma SA do?

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments.